SCHEMBL3910153

SCHEMBL3910153

O=C1CCCN1C1(c2cccc(F)c2)CCNCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 2/20 0.40
SLC6A9 P48067 2/20 0.40
ALOX5 P09917 1/20 0.40
ALDH1A1 P00352 3/20 0.39
USP2 O75604 2/20 0.39
CYP2D6 P10635 2/20 0.39
CYP2C19 P33261 1/20 0.39
CYP3A4 P08684 1/20 0.39
ALOX15 P16050 1/20 0.38
SLC6A2 P23975 4/20 0.37
SLC6A4 P31645 2/20 0.37
SLC6A3 Q01959 2/20 0.37
HSD11B1 P28845 1/20 0.36
HSD11B2 P80365 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
NPC1 O15118 1/20 0.36
TP53 P04637 1/20 0.36
GLA P06280 1/20 0.36
PKM P14618 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3911083 0.84 GABRD (0.41) OPRM1SLC6A9ALOX5HSD11B1HSD11B2
SCHEMBL3909117 0.83 SLC6A4 (0.35) ALDH1A1USP2CYP2D6CYP2C19CYP3A4
SCHEMBL27698338 0.81 PRMT6 (0.37) ALOX5ALDH1A1CYP2D6CYP2C19MEN1
SCHEMBL3900550 0.80 USP2 (0.38) OPRM1SLC6A9ALDH1A1USP2CYP2D6
SCHEMBL3973464 0.78 BACE1 (0.48) OPRM1ALDH1A1CYP2D6CYP2C19CYP3A4
SCHEMBL3902260 0.75 GABRD (0.40) OPRM1SLC6A9ALOX5ALDH1A1CYP2C19
SCHEMBL27679281 0.75 KMT2A (0.34) ALDH1A1USP2MEN1KMT2ATP53
SCHEMBL4120082 0.73 OPRM1 (0.42) OPRM1SLC6A9ALDH1A1USP2CYP2D6
Hydrochloric Acid SCHEMBL2329545 0.72 OPRM1 (0.41) OPRM1SLC6A9ALDH1A1USP2CYP2D6
SCHEMBL4503607 0.72 GRIN1 (0.46) OPRM1SLC6A9ALDH1A1SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1773823-B1 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2013-08-21 EP disclosed
CN-101006084-B 4-arylmorpholin-3-one derivatives, preparation method and therapeutic use thereof SANOFI AVENTIS 2010-09-08 CN disclosed
US-7521449-B2 4-arylmorpholin-3-one derivatives, their preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2009-04-21 US disclosed
CN-101006084-A 4-arylmorpholin-3-one derivatives, preparation method and therapeutic use thereof SANOFI AVENTIS (FR) 2007-07-25 CN disclosed
US-20070142349-A1 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2007-06-21 US disclosed
EP-1773823-A1 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2007-04-18 EP disclosed
WO-2006021654-A1 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142349-A1 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF ADRB3, ADRA2C, OPRK1 OPRM1 5/4885SLC6A9 3743/4885ALOX5 1508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.